Articles tagged "Induction therapy"

2018 American Transplant Congress
Emergence of a Costimulation-Susceptible T Cell Repertoire Post-Alemtuzumab Induction
Q. Gao,¹ A. Mehta,² A. Guasch,² L. Stempora,¹ A. Kirk,¹ H. Xu.¹
¹Department of Surgery, Duke University Medical Center, Durham, NC; ²Emory Transplant Center, Emory University School of Medicine, Atlanta, GA.
Kidney transplant patients treated with belatacept-based regimens without depletional induction have higher rates of costimulation blockade resistant rejection (CoBRR). In contrast, belatacept effectively prevents rejection…
2018 American Transplant Congress
The Influence of Rabbit Antithymocyte Globulin (rATG) Dose on the Incidence of CMV Infection in Kidney Transplant Recipients Receiving No Pharmacological Prophylaxis. A Propensity Score Matched Cohort Analysis
M. Ivani de Paula,^1,2 S. Bae,¹ J. Garonzik-Wang,¹ C. Felipe,² M. Cristelli,² A. Massie,^1,3 J. Medina-Pestana,² D. Segev,^1,3 H. Tedesco Silva J�nior.²
¹Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD; ²Department of Nephrology, Hospital do Rim, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; ³Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD, Brazil.
rATG has become the agent of choice for induction therapy in sensitized patients and those receiving expanded criteria donors (ECD) allografts. However, the optimal dose…
2018 American Transplant Congress
T-Cell Depletion Does Not Increase the Risk of CMV Infection in Donor-Positive, Recipient-Negative Kidney Transplants Due to the Absence of Preformed CMV-Specific Cell-Mediated Immunity
M. Jarque,¹ H. Kaminski,² L. Couzi,² E. Crespo,¹ J. Déchanet-Merville,³ S. Luque,¹ N. Montero,⁴ M. Pascual,⁵ O. Manuel,^5,6 P. Merville,² O. Bestard.^1,4
¹Nephrology Lab, IDIBELL, Barcelona, Spain; ²Nephrology Dep, Hôpital Pellegrin, Bordeaux, France; ³National Center of Scientific Research, Bordeaux, France; ⁴Nephrology Dep, Bellvitge Hospital, Barcelona, Spain; ⁵Transplantation Center, Lausanne Hospital, Lausanne, Switzerland; ⁶Infectious Diseases Dep, Lausanne Hospital, Lausanne, Switzerland.
Kidney transplants (KT) with R-/D+ CMV serostatus receiving T-cell depletion induction are considered as the highest risk population for CMV infection and long-lasting prophylaxis therapy…
2018 American Transplant Congress
Cost Impacts of Alternative Kidney Transplant Immunosuppression: A National Cohort Study
K. Lentine,¹ D. Axelrod,² V. Dharnidharka,³ H. Xiao,¹ D. Brennan,⁴ D. Segev,⁴ H. Randall,¹ R. Ouseph,¹ A. Naik,⁵ N. Lam,⁶ T. Alhamad,³ B. Kasiske,⁷ G. Hess,⁸ M. Schnitzler.¹
¹Saint Louis Univ, St. Louis; ²Lahey Clinic, Burlington; ³Washington Univ, St. Louis; ⁴Johns Hopkins, Baltimore; ⁵Univ Michigan, Ann Arbor; ⁶Univ Alberta, Edmonton, Canada; ⁷Hennepin County, Minneapolis; ⁸Symphony Health, Conshohocken.
Economic outcomes are increasingly considered along with clinical efficacy to guide choice of alternative therapies. We examined the cost impact of kidney transplant (KTx) induction…
2018 American Transplant Congress
Anti-Thymocyte Globulin vs. Alemtuzumab: A Comparison of Long-Term Outcomes among Renal Transplant Recipients
E. Loncharic, A. Dodson, K. Gutierrez.
Department of Pharmacy, The University of Alabama at Birmingham, Birmingham, AL.
Background: Two lymphocyte depleting agents are currently available for renal transplant induction: alemtuzumab (C1H) and rabbit anti-thymocyte globulin (rATG). Studies comparing long-term outcomes between C1H…
2018 American Transplant Congress
Alemtuzumab is Associated with Higher Rates of De Novo Donor Specific Antibody (DSA) in Patients with No Pre-Transplant DSA
N. Bath, S. Parajuli, G. Leverson, M. Jorgenson, J. Fose, T. Ellis, D. Kaufman, A. Djamali, R. Redfield.
Surgery, University of Wisconsin, Madison, WI.
Introduction: Basiliximab, alemtuzumab, and thymoglobulin are the most commonly used induction agents in the US. While many centers use depleting antibody induction therapy in patients…
2018 American Transplant Congress
Ideal Body Weight versus Actual Body Weight for Rabbit Antithymocyte Globulin Induction in Pancreas Transplantation
E. Martinez,¹ D. Felix,² J. Wiegel,² T. Al-Qaoud,¹ G. Leverson,¹ A. Condon,² R. Redfield,¹ J. Odorico.¹
¹Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI; ²Department of Pharmacy, UW Health, Madison, WI.
Purpose: Rabbit antithymocyte globulin (rATG) is the most commonly used induction agent in solid organ pancreas transplantation. The optimal induction dosing of rATG, has not…
2018 American Transplant Congress
Alemtuzumab Induction is Effective and Safe in Elderly Kidney Transplant Recipients
A. Toledo, K. Szempruch, P. Serrano, K. Andreoni, T. Kozlowski.
University of North Carolina, Chapel Hill.
Purpose of this study is to determine safety of Alemtuzumab (Ab) in elderly kidney recipients.MethodsThis is a retrospective single center cohort analysis concerning kidney transplant…
2018 American Transplant Congress
Decreased Long-Term Survival with Antithymocyte Globulin Induction in Elderly Kidney Transplant Recipients
I. Bajjoka, A. Yaldo, C. Crombez, M. Abouljoud.
Henry Ford Transplant Institute, Detroit, MI.
Purpose: Long-term consequences of immunosuppression on the elderly is still unclear. This data to evaluates long-term outcomes for younger (Y) versus elderly (E) kidney transplant…
2018 American Transplant Congress
Safety and Efficacy of Rabbit Anti-Thymocyte Globulin Induction in Pediatric Patients Undergoing Cardiac Transplantation
M. Sell,¹ A. Haney,¹ K. Sprott,¹ A. Burnette,² H. Henderson,² A. Savage.²
¹Pharmacy, Medical University of South Carolina, Charleston, SC; ²Cardiac Transplant, Medical University of South Carolina, Charleston, SC.
Purpose: Limited data are available in pediatric cardiac transplant patients that focus on the safety and efficacy of rabbit anti-thymocyte globulin (rATG) induction therapy. The…